Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review summarizes recent advances in nanomedicine-based therapies for psoriasis, highlighting their potential to provide targeted and sustained therapeutic effects by modulating key cellular components and signaling pathways involved in the disease, offering novel perspectives for future treatment development.

This case report is the first to document the coexistence of bullous pemphigoid, malignant tumors, and alopecia areata in a patient, highlighting the complete resolution of skin lesions with dupilumab and spontaneous hair regrowth without disease-specific treatment.

This case study reports a young male with alopecia universalis experienced significant hair whitening following baricitinib treatment, highlighting the need for further research on JAK inhibitors' impact on hair pigmentation and their underlying mechanisms.

The study reported that patients with alopecia areata had significantly higher serum levels of IL-17A and IL-2 compared to healthy controls, suggesting these interleukins may play an important role in the disease, though they did not correlate with its severity or duration.

In this mini-review, recent insights suggest a possible role of type-2-related immunity in diseases like alopecia areata, vitiligo, and localized scleroderma, though whether this immune response benefits or worsens these conditions remains unclear.

This case report describes a 12-year-old boy with severe atopic dermatitis and comorbid alopecia areata who experienced complete hair regrowth and improved skin condition after 3 months of oral abrocitinib treatment, with no adverse reactions observed during a 1-year follow-up period.

This review explores the inflammatory pathogenesis and clinical presentation of hidradenitis suppurativa, highlighting the complexity of treatment and the impact on patients' quality of life, while also examining emerging therapeutic options.

This report details a case of severe alopecia areata developing one month after COVID-19 infection in a 20-year-old woman, suggesting a possible connection between COVID-19 and the condition's onset.

This review examines current treatments for alopecia areata, noting that topical corticosteroids are commonly used first in children, while more advanced cases may require systemic therapies to modulate the immune system; it reports no new clinical results.

This study found no significant difference in serum prolactin levels between vitiligo patients and healthy controls, nor any significant association between prolactin gene polymorphism and vitiligo severity, except for a significant relation with BMI.

This mini review discusses cellular plasticity in cutaneous wound healing and reports no clinical results; the authors aim to enhance regenerative medicine by examining underlying mechanisms.

In this study, researchers found that alopecia areata patients show a significant reduction in suppressive regulatory T-cells and an increase in inflammatory T-cell populations, suggesting an immunological imbalance contributing to the disease.

This study found that Mentha suaveolens aqueous extract activated Nrf-2 and increased detoxifying enzyme expression in keratinocytes, providing protection against oxidative stress without cytotoxicity.

This study found that claudins CLDN1 and CLDN3 are crucial for maintaining proper hair follicle structure in mice, and their dysregulation may lead to telogen hair loss.

This study found that terminally differentiated effector memory Vδ1T-cells and their cytotoxic activation markers were elevated in alopecia areata patients, suggesting these cells may contribute to its early pathogenesis.

The researchers reported that nicotinic acid normalized excessive sebaceous lipogenesis without affecting basal lipogenesis and suggested potential anti-acne benefits.

This study found that orally administering the CCR5 inhibitor Maraviroc improved hair loss in 4 out of 5 mice with alopecia areata and also reduced the development of the condition, evidenced by decreased CCR5+ T-cell infiltration in treated mice.

This study reports that the loss of Langerhans cells in lichen planopilaris scars may be linked to the downregulation of ITG αvβ6, which is not seen in other scar formation diseases.

This study suggests that the outer root sheath of human hair follicles may act as a "metabolic center," capable of synthesizing glucose from lactate, which supports glycogen metabolism.

This study reports that 71% of patients treated with the gamma-secretase inhibitor PF-03084014 for desmoid tumors experienced dermatologic side effects, such as follicular lesions and pruritic eruptions, which were managed with topical or systemic treatments.

This study found that the activity of CD73, an enzyme expressed in the hair follicle epithelium, may regulate human hair growth by modulating adenosine production.

This study reported improvement in hair loss lesions in C3H/HeJ mice with alopecia areata following treatment with the CCR5 inhibitor maraviroc, alongside reduced infiltration of specific T cells in the lesions.

This study found that stimulating olfactory receptor OR2AT4 in human hair follicles with Sandalore® may slow catagen development and reduce keratinocyte apoptosis, suggesting potential implications for hair growth management.

This review discusses medications used in dermatology, detailing their side effects and interactions, and reports no new clinical results.

This case report identifies alopecia universalis as a probable adverse drug reaction to adalimumab in a patient with psoriasis and psoriatic arthritis.

This review discusses the epidemiology and cutaneous manifestations of lupus erythematosus, highlighting comparable incidence rates between cutaneous and systemic forms, but reports no new findings.

In this study, estradiol was found to increase VEGF expression in cultured dermal papilla cells at physiological levels similar to pregnancy, suggesting that declining estrogen might contribute to female pattern hair loss in older Japanese women.

In this case report, a female patient with both psoriasis and lichen planus initially responded to acitretin and topical mometasone but experienced a relapse after stopping the treatment. The authors reported marked improvement within 3 months after switching to upadacitinib, aiming to guide clinical decision-making.

This case report describes how changing treatment from adalimumab to guselkumab successfully controlled both pustulotic arthro-osteitis and paradoxical skin reactions in a patient with palmoplantar pustulosis.

In this case report, a patient with severe erythrodermic psoriasis and diffuse alopecia who was unresponsive to conventional treatments showed complete resolution of skin lesions and alopecia after being treated with ixekizumab.